• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在急性川崎病患者开始初始治疗前预测其对标准高剂量γ-球蛋白治疗无反应的情况。

Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment.

作者信息

Sano Tetsuya, Kurotobi Shunji, Matsuzaki Kouji, Yamamoto Takehisa, Maki Ichiro, Miki Kazunori, Kogaki Shigetoyo, Hara Junichi

机构信息

Department of Pediatrics, Osaka Kosei-Nenkin Hospital, 4-2-78 Fukushima, Fukushima-ku, Osaka City, Osaka 553-0003, Japan.

出版信息

Eur J Pediatr. 2007 Feb;166(2):131-7. doi: 10.1007/s00431-006-0223-z. Epub 2006 Aug 1.

DOI:10.1007/s00431-006-0223-z
PMID:16896641
Abstract

Clinical, laboratory, and echocardiographic data were retrospectively analyzed in 112 patients with acute Kawasaki disease who received high-dose (2 g/kg) intravenous gamma-globulin (IVIG) treatment within 2 days and were compared for those who were responsive and non-responsive to initial IVIG treatment. Coronary arteries adjusted for body surface area (BSA) were evaluated quantitatively by comparison with the mean dimensions for 85 normal control subjects. The incidence of coronary abnormalities was higher in IVIG-non-responsive patients as compared to IVIG-responsive patients (71% versus 5%, p<0.0001). Univariate analysis of pre-IVIG data showed that the neutrophil count and serum levels of C-reactive protein (CRP), total bilirubin (TB), aspartate aminotransferase (AST), alanine aminotransferase, and lactate dehydrogenase (LDH) were significantly higher in IVIG-non-responsive versus responsive patients. Multivariate analysis selected CRP (p=0.009), TB (p<0.001), and AST (p=0.002) as independent predictors of non-responsiveness to initial IVIG treatment. By defining predictive values, patients with at least two of three predictors (CRP>or=7.0 mg, TB>or=0.9 mg, or AST>or=200 IU/L) are considered to be non-responsive to IVIG for acute Kawasaki disease. Alternatively, more intense initial therapy may be a promising therapeutic strategy for patients who are predicted to be IVIG-non-responsive.

摘要

对112例急性川崎病患者的临床、实验室及超声心动图数据进行回顾性分析,这些患者在2天内接受了高剂量(2g/kg)静脉注射丙种球蛋白(IVIG)治疗,并对初始IVIG治疗有反应和无反应的患者进行比较。通过与85名正常对照受试者的平均尺寸比较,对根据体表面积(BSA)调整后的冠状动脉进行定量评估。与IVIG反应型患者相比,IVIG无反应型患者的冠状动脉异常发生率更高(71%对5%,p<0.0001)。IVIG治疗前数据的单因素分析显示,IVIG无反应型患者的中性粒细胞计数以及血清C反应蛋白(CRP)、总胆红素(TB)、天冬氨酸转氨酶(AST)、丙氨酸转氨酶和乳酸脱氢酶(LDH)水平显著高于反应型患者。多因素分析选择CRP(p=0.009)、TB(p<0.001)和AST(p=0.

相似文献

1
Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment.在急性川崎病患者开始初始治疗前预测其对标准高剂量γ-球蛋白治疗无反应的情况。
Eur J Pediatr. 2007 Feb;166(2):131-7. doi: 10.1007/s00431-006-0223-z. Epub 2006 Aug 1.
2
Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset.川崎病发病时静脉注射大剂量丙种球蛋白治疗无反应性的预测
J Pediatr. 2000 Aug;137(2):172-6. doi: 10.1067/mpd.2000.104815.
3
[Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].[三种静脉注射丙种球蛋白方案对小儿川崎病及相关冠状动脉并发症发生率的影响:一项对比研究]
Zhonghua Yi Xue Za Zhi. 2007 Nov 27;87(44):3119-21.
4
Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease.以脉冲式甲泼尼龙联合丙种球蛋白作为急性川崎病的初始治疗方法。
Eur J Pediatr. 2009 Feb;168(2):181-5. doi: 10.1007/s00431-008-0727-9. Epub 2008 Apr 30.
5
Intravenous immune globulin plus corticosteroids in refractory Kawasaki disease.静脉注射免疫球蛋白联合皮质类固醇治疗难治性川崎病。
Pediatr Int. 2011 Oct;53(5):729-735. doi: 10.1111/j.1442-200X.2011.03338.x.
6
Evaluation of laboratory predictors for intravenous immunoglobulin resistance and coronary artery aneurysm in Kawasaki Disease before and after therapy.治疗前后川崎病患者静脉注射免疫球蛋白抵抗和冠状动脉瘤的实验室预测因子评估。
Clin Rheumatol. 2023 Jan;42(1):167-177. doi: 10.1007/s10067-022-06366-x. Epub 2022 Sep 21.
7
Serum amyloid A as a biomarker for immunoglobulin resistance in Kawasaki disease.血清淀粉样蛋白 A 作为川崎病免疫球蛋白抵抗的生物标志物。
Ann Med. 2023;55(2):2264315. doi: 10.1080/07853890.2023.2264315. Epub 2023 Oct 23.
8
Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease.血清白蛋白水平预测川崎病初始静脉注射免疫球蛋白治疗失败。
Acta Paediatr. 2010 Oct;99(10):1578-83. doi: 10.1111/j.1651-2227.2010.01875.x. Epub 2010 Jun 7.
9
A comparison of serum IL6 and CRP levels with respect to coronary changes and treatment response in Kawasaki disease patients: a prospective study.一项前瞻性研究比较了川崎病患者血清 IL6 和 CRP 水平与冠状动脉变化和治疗反应的关系。
Rheumatol Int. 2019 Oct;39(10):1797-1801. doi: 10.1007/s00296-019-04375-9. Epub 2019 Jul 13.
10
High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.高剂量阿司匹林与贫血相关,且对川崎病的疾病转归无益处。
PLoS One. 2015 Dec 10;10(12):e0144603. doi: 10.1371/journal.pone.0144603. eCollection 2015.

引用本文的文献

1
Association between C-reactive protein-albumin-lymphocyte (CALLY) index with intravenous immunoglobulin non-response in Kawasaki disease.川崎病中C反应蛋白-白蛋白-淋巴细胞(CALLY)指数与静脉注射免疫球蛋白无反应性之间的关联
Ann Med. 2025 Dec;57(1):2548023. doi: 10.1080/07853890.2025.2548023. Epub 2025 Aug 20.
2
Immunophenotype of Kawasaki Disease: Insights into Pathogenesis and Treatment Response.川崎病的免疫表型:对发病机制和治疗反应的见解
Life (Basel). 2025 Jun 25;15(7):1012. doi: 10.3390/life15071012.
3
Predictive value of lymphocyte-to-C-reactive protein ratio for predicting initial and repeated intravenous immunoglobulin resistance in a large cohort of Kawasaki disease: a prospective cohort study.

本文引用的文献

1
Treatment of intravenous immunoglobulin-resistant Kawasaki disease with methotrexate.用甲氨蝶呤治疗静脉注射免疫球蛋白抵抗性川崎病。
Scand J Rheumatol. 2005 Mar-Apr;34(2):136-9. doi: 10.1080/03009740510026328.
2
Infliximab treatment for refractory Kawasaki syndrome.英夫利昔单抗治疗难治性川崎综合征。
J Pediatr. 2005 May;146(5):662-7. doi: 10.1016/j.jpeds.2004.12.022.
3
Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.
淋巴细胞与C反应蛋白比值对一大群川崎病患者初始及反复静脉注射免疫球蛋白抵抗的预测价值:一项前瞻性队列研究
Eur J Pediatr. 2025 Jul 9;184(8):472. doi: 10.1007/s00431-025-06296-1.
4
Heterogeneity in Kawasaki disease patients with coronary artery abnormalities investigated by data-driven cluster analysis.通过数据驱动的聚类分析研究川崎病合并冠状动脉异常患者的异质性。
Pediatr Res. 2025 Jun 20. doi: 10.1038/s41390-025-04205-8.
5
Interpretable web-based machine learning model for predicting intravenous immunoglobulin resistance in Kawasaki disease.用于预测川崎病静脉注射免疫球蛋白抵抗的基于网络的可解释机器学习模型。
Ital J Pediatr. 2025 Jun 9;51(1):181. doi: 10.1186/s13052-025-02036-1.
6
Risk factors associated with persistent coronary artery lesions in children with Kawasaki disease in an Italian cohort.意大利队列中川崎病患儿持续性冠状动脉病变的相关危险因素。
Eur J Pediatr. 2025 May 31;184(6):377. doi: 10.1007/s00431-025-06162-0.
7
Limited Performance of Machine Learning Models Developed Based on Demographic and Laboratory Data Obtained Before Primary Treatment to Predict Coronary Aneurysms.基于初次治疗前获得的人口统计学和实验室数据开发的机器学习模型预测冠状动脉瘤的性能有限。
Biomedicines. 2025 Apr 29;13(5):1073. doi: 10.3390/biomedicines13051073.
8
Value of cystatin C for Kawasaki disease with coronary artery aneurysm.胱抑素C在川崎病合并冠状动脉瘤中的价值。
Transl Pediatr. 2025 Apr 30;14(4):545-558. doi: 10.21037/tp-2024-516. Epub 2025 Apr 27.
9
IVIG Resistance in Kawasaki Disease: Clinical and Laboratory Risk Factors and the Potential Role of Administration Timing.川崎病中的静脉注射免疫球蛋白抵抗:临床和实验室风险因素以及给药时机的潜在作用
J Inflamm Res. 2025 May 2;18:5923-5929. doi: 10.2147/JIR.S513963. eCollection 2025.
10
Learning-Based Models for Predicting IVIG Resistance and Coronary Artery Lesions in Kawasaki Disease: A Review of Technical Aspects and Study Features.基于学习的川崎病静脉注射免疫球蛋白抵抗和冠状动脉病变预测模型:技术方面与研究特征综述
Paediatr Drugs. 2025 Apr 3. doi: 10.1007/s40272-025-00693-7.
川崎病的诊断、治疗及长期管理:美国心脏协会青少年心血管疾病理事会风湿热、心内膜炎及川崎病委员会给卫生专业人员的声明
Circulation. 2004 Oct 26;110(17):2747-71. doi: 10.1161/01.CIR.0000145143.19711.78.
4
Association of vascular endothelial growth factor (VEGF) and VEGF receptor gene polymorphisms with coronary artery lesions of Kawasaki disease.血管内皮生长因子(VEGF)及VEGF受体基因多态性与川崎病冠状动脉病变的关联
Pediatr Res. 2004 Dec;56(6):953-9. doi: 10.1203/01.PDR.0000145280.26284.B9. Epub 2004 Oct 6.
5
Enhanced iNOS expression in leukocytes and circulating endothelial cells is associated with the progression of coronary artery lesions in acute Kawasaki disease.白细胞和循环内皮细胞中诱导型一氧化氮合酶(iNOS)表达增强与急性川崎病冠状动脉病变的进展相关。
Pediatr Res. 2004 Apr;55(4):688-94. doi: 10.1203/01.PDR.0000113464.93042.A4. Epub 2004 Feb 5.
6
Novel and traditional cardiovascular risk factors in children after Kawasaki disease: implications for premature atherosclerosis.川崎病患儿的新型和传统心血管危险因素:对过早动脉粥样硬化的影响。
J Am Coll Cardiol. 2004 Jan 7;43(1):120-4. doi: 10.1016/j.jacc.2003.08.030.
7
Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial.皮质类固醇在川崎病初始治疗中的应用:一项随机试验报告
J Pediatr. 2003 Jun;142(6):611-6. doi: 10.1067/mpd.2003.191.
8
Plasminogen activator inhibitor-1 in patients with Kawasaki disease: diagnostic value for the prediction of coronary artery lesion and implication for a new mode of therapy.川崎病患者中的纤溶酶原激活物抑制剂-1:对冠状动脉病变预测的诊断价值及对新治疗模式的启示
Pediatr Res. 2003 Jun;53(6):983-8. doi: 10.1203/01.PDR.0000061566.63383.F4. Epub 2003 Mar 5.
9
Immunoglobulin failure and retreatment in Kawasaki disease.川崎病中的免疫球蛋白治疗失败与再次治疗
Pediatr Cardiol. 2003 Mar-Apr;24(2):145-8. doi: 10.1007/s00246-002-0216-2. Epub 2002 Dec 4.
10
Coronary diameter in normal infants, children and patients with Kawasaki disease.正常婴儿、儿童及川崎病患者的冠状动脉直径。
Pediatr Int. 2002 Feb;44(1):1-4. doi: 10.1046/j.1442-200x.2002.01508.x.